Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 2/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | FAP | Q12884 | 2/20 | 0.40 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CPT2 | P23786 | 2/20 | 0.39 |
| ▸ | CPT1A | P50416 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20187751 | 1.00 | PTGER4 (0.40) | PTGER4ELANEFAPCTRB1F2 | |
| SCHEMBL20188058 | 0.89 | DPP4 (0.43) | PTGER4ELANECTRB1F2PRSS1 | |
| SCHEMBL20188054 | 0.89 | DPP4 (0.43) | PTGER4ELANECTRB1F2PRSS1 | |
| SCHEMBL20188440 | 0.88 | F2 (0.45) | PTGER4ELANECTRB1F2PRSS1 | |
| SCHEMBL20188311 | 0.88 | F2 (0.45) | PTGER4ELANECTRB1F2PRSS1 | |
| SCHEMBL23863889 | 0.86 | F2 (0.46) | ELANECTRB1F2PRSS1DPP4 | |
| SCHEMBL20859032 | 0.86 | F2 (0.46) | ELANECTRB1F2PRSS1DPP4 | |
| SCHEMBL24448344 | 0.86 | DPP4 (0.46) | ELANEFAPCTRB1F2PRSS1 | |
| SCHEMBL28389317 | 0.85 | DPP4 (0.46) | ELANECTRB1F2PRSS1DPP4 | |
| SCHEMBL18094995 | 0.85 | DPP4 (0.46) | ELANECTRB1F2PRSS1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358935-B2 | Prodrugs of lanicemine and their method of use | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2022-06-14 | — | — | US | claimed |
| US-20200299238-A1 | PRODRUGS OF LANICEMINE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD. | 2020-09-24 | — | — | US | claimed |
| WO-2018098344-A1 | PRODRUGS OF LANICEMINE AND THEIR METHOD OF USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2018-05-31 | — | — | WO | claimed |
| US-11358935-B2 | Prodrugs of lanicemine and their method of use | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20200299238-A1 | PRODRUGS OF LANICEMINE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD. | 2020-09-24 | — | — | US | disclosed |
| WO-2018098344-A1 | PRODRUGS OF LANICEMINE AND THEIR METHOD OF USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299238-A1 | PRODRUGS OF LANICEMINE AND THEIR METHOD OF USE | GRIN3A, GRIN1, GRM3 | PTGER4 3342/4885ELANE 1124/4885FAP 1258/4885 |
| US-11358935-B2 | Prodrugs of lanicemine and their method of use | GRIN3A, GRIN1, GRM3 | PTGER4 3342/4885ELANE 1124/4885FAP 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.